Goldman initiated coverage on Erasca with a new price target
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Erasca with a rating of Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $5.00 | Outperform | Raymond James |
| 11/18/2024 | $6.00 | Buy | Jefferies |
| 3/11/2024 | $8.00 | Overweight | CapitalOne |
| 1/5/2024 | $11.00 → $6.00 | Buy → Neutral | BofA Securities |
| 10/11/2023 | $10.00 | Buy | H.C. Wainwright |
| 3/30/2023 | $9.00 | Buy | Mizuho |
| 2/24/2023 | $10.00 | Buy | Goldman |
| 2/3/2023 | $15.00 | Equal-Weight → Overweight | Morgan Stanley |
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patie
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences. Jefferies Global Healthcare Conference (June 3-5, 2025)Location: New York, NYFormat: Fireside ChatDate and Time: Wednesday, June 4, 5:30 pm Eastern Time Goldman Sachs 46th Annual Global Healthcare Conference (June 9-11, 2025)Location: Miami Beach, FLFormat: Firesi
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended M